Current and future directions of deep brain stimulation for neurological and psychiatric disorders.

Current and future directions of deep brain stimulation for neurological and psychiatric disorders. J Neurosurg. 2019 Aug 01;131(2):333-342 Authors: Lee DJ, Lozano CS, Dallapiazza RF, Lozano AM Abstract Deep brain stimulation (DBS) has evolved considerably over the past 4 decades. Although it has primarily been used to treat movement disorders such as Parkinson's disease, essential tremor, and dystonia, recently it has been approved to treat obsessive-compulsive disorder and epilepsy. Novel potential indications in both neurological and psychiatric disorders are undergoing active study. There have been significant advances in DBS technology, including preoperative and intraoperative imaging, surgical approaches and techniques, and device improvements. In addition to providing significant clinical benefits and improving quality of life, DBS has also increased the understanding of human electrophysiology and network interactions. Despite the value of DBS, future developments should be aimed at developing less invasive techniques and attaining not just symptom improvement but curative disease modification. PMID: 31370011 [PubMed - in process]
Source: Journal of Neurosurgery - Category: Neurosurgery Authors: Tags: J Neurosurg Source Type: research

Related Links:

ConclusionIt is envisaged that the current review will add value to more scientific research on M. flabellifolius and enhance/promote the increased interest in the sustainable commercialization of M. flabellifolius herbal tea as well as lead to the validation of unverified ethnobotanical claims.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 17 January 2020Source: Neurochemistry InternationalAuthor(s): Pamela R. Westmark, Alejandra Gutierrez, Aaron K. Gholston, Taralyn M. Wilmer, Cara J. WestmarkAbstractThe ketogenic diet is highly effective at attenuating seizures in refractory epilepsy and accumulating evidence in the literature suggests that it may be beneficial in autism. To our knowledge, no one has studied the ketogenic diet in any fragile X syndrome (FXS) model. FXS is the leading known genetic cause of autism. Herein, we tested the effects of chronic ketogenic diet treatment on seizures, body weight, ketone and glucos...
Source: Neurochemistry International - Category: Neuroscience Source Type: research
Medtronic continues to develop products for deep brain stimulation (DBS) for the treatment of movement disorders including Parkinson ’s disease (PD), essential tremor (ET), dystonia, and other neurological disorders such as epilepsy and obsessive-compulsive disorder (OCD). As part of the development process, the effectiveness and safety of new products must be evaluated before initiation of clinical trials. While some evaluatio ns can be performed with bench testing and simulation, regulatory agencies often require in vivo testing in preclinical animal models.
Source: BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation - Category: Neurology Authors: Source Type: research
Deep brain stimulation (DBS) is an established therapy to treat several neurological disorders (e.g. essential tremor, Parkinson ’s disease, dystonia, obsessive-compulsive disorder) (Benabid et al., 1991; Greenberg et al., 2010; Obeso et al., 2001; Vidailhet et al., 2005) and its efficacy is being explored for a range of additional indications (e.g. epilepsy, treatment-resistant depression, neuropathic pain, Tourette syndro me) (Fisher et al., 2010; Holtzheimer, 2012; Lempka et al., 2017; Malone et al., 2009; Morrell and RNS System in Epilepsy Study Group, 2011; Schrock et al., 2015).
Source: Clinical Neurophysiology - Category: Neuroscience Authors: Source Type: research
This article is protected by copyright. All rights reserved.
Source: European Journal of Neurology - Category: Neurology Authors: Tags: Editorials Source Type: research
Nexeon Medsytems is a medical device company focused on providing innovative neurostimulation products for patients suffering from debilitating neurological diseases, including Parkinson’s and essential tremor. It was founded in 2005 with ...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Neurology Neurosurgery Source Type: blogs
Medtronic (NYSE:MDT) said today that it won CE Mark approval in the European Union for its SureTune3 deep-brain stimulation software, which is designed to map lead locations and indicate the level of stimulation. The Fridley, Minn.-based Medtronic said its DBS devices are approved in the E.U. for treating Parkinson’s disease, dystonia, essential tremor, obsessive-compulsive disorder and epilepsy, claiming the portfolio as the only one to be full-body MR-conditional and able to operate during MRI scans. and is the only DBS complete portfolio that, under specific conditions, is full body MR conditional and can be ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Neuromodulation/Neurostimulation Regulatory/Compliance Medtronic Source Type: news
The application of stereotactic surgery in patients with movement disorders, epilepsy, and psychiatric disorders has substantially increased with the introduction of modern deep brain stimulation (DBS). The therapeutic effects in patients with Parkinson's disease [1–3], tremor [4], dystonia [5,6], Tourette syndrome (TS) [7] and obsessive-compulsive disorder (OCD) [8,9] are well established. We have learned more about the complications of DBS with the increase in the number of treated patients, and developed strategies to manage them [10,11].
Source: Clinical Neurology and Neurosurgery - Category: Neurosurgery Authors: Source Type: research
Authors: Sugiyama K, Nozaki T, Asakawa T, Koizumi S, Saitoh O, Namba H Abstract The use of electrical stimulation to treat pain in human disease dates back to ancient Rome or Greece. Modern deep brain stimulation (DBS) was initially applied for pain treatment in the 1960s, and was later used to treat movement disorders in the 1990s. After recognition of DBS as a therapy for central nervous system (CNS) circuit disorders, DBS use showed drastic increase in terms of adaptability to disease and the patient's population. More than 100,000 patients have received DBS therapy worldwide. The established indications for DBS...
Source: Neurologia Medico-Chirurgica - Category: Neurosurgery Tags: Neurol Med Chir (Tokyo) Source Type: research
CONCLUSIONS: FDA has currently approved use of deep brain stimulation for treatment of essential tremor, Parkinson’s disease, dystonia and Obsessive-Compulsive Disorder where it has acquired great achievement. The future of DBS is encouraging with a great potential to treat a wide array of diseases. Study Supported: NoneDisclosure: Dr. Davis has nothing to disclose.
Source: Neurology - Category: Neurology Authors: Tags: History of Neurology Source Type: research
More News: Brain | Deep Brain Stimulation | Dystonia | Epilepsy | Neurology | Neurosurgery | Obsessive Compulsive Disorder | Parkinson's Disease | Psychiatry | Study